Simplify Propel Opportunities ETF
$18.90−0.33 (−1.73%)
- Expense ratio
- 2.82%
- Fund size
- $83M
- 1Y return
- +43.5%
- Yield · Last 12 months
- 14.14%
- Holdings
- 19
- Volume · 30D
- 0M sh
- NAV per share
- $19.18
- 52W range
The ETF.net SURI Grade
Score 16 of 100 sits in the F band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.FScore 2Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.DScore 25Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.FScore 12Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.DScore 28Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.BScore 66Category rank
Our read on SURI
FA life-sciences venture shop in an ETF wrapper: Propel Bio's scientists hunt overlooked biotech and pharma, using preferreds, convertibles and structured notes alongside common stock. Pricing is private-fund steep.
The Fund seeks long-term capital appreciation.
Why people hold it
- Sub-advised by Propel Bio Management, a life-science investment firm whose team includes scientists and drug developers rather than generalist stock pickers.sec.govconvention.bio.org
- Wider toolkit than most healthcare funds: common and preferred stock, convertible bonds, structured notes and corporate debt, all inside a 1940 Act ETF.aaii.com
- Actively run and concentrated by design, aiming at global biotech, pharma, health tech and life-science tools names the manager judges overlooked.simplify.us
Worth knowing
- Costs 2.82% a year, built on a 2.75% base advisory fee for the first $1B of assets. Broad active core funds like DFAC or AVLC charge a small fraction of that.simplify.us
- A small fund that trades lightly, so bid-ask spreads can run wider than in mainstream healthcare ETFs.
- Non-diversified and tied to one sector, so a few clinical readouts can swing the whole portfolio.aaii.com
SURI Holdings
- Stocks
- 19
- 82%
- PAGP
Sectors
- Health Care53.9%
- Energy46.1%
Geography
- United States92.62%
- Canada3.81%
- United Kingdom2.12%
- France1.46%
SURI Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | SURI |
|---|---|
| Year to date | +25.2% |
| 1 month | −3.0% |
| 3 months | +17.1% |
| 1 year | +43.5% |
| 3 years | +13.4% |
| 5 years | — |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | SURI |
|---|---|---|
| 2026 YTD | +25.2% | |
| 2025 | +28.3% | |
| 2024 | −13.2% | |
| 2023 | −3.0% |
SURI in the news
ETF.net Research hasn’t filed on SURI yet — coverage lands here as it’s written.
SURI Dividends
- 14.14%
- $2.72
- $0.68 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Jun 25, 2026 | Jun 30, 2026 | $0.68 |
| Mar 26, 2026 | Mar 31, 2026 | $0.68 |
| Dec 23, 2025 | Dec 31, 2025 | $0.68 |
| Sep 25, 2025 | Sep 30, 2025 | $0.68 |
| Jun 25, 2025 | Jun 30, 2025 | $0.68 |
| Mar 26, 2025 | Mar 31, 2025 | $0.68 |
| Dec 23, 2024 | Dec 31, 2024 | $0.68 |
| Sep 25, 2024 | Sep 30, 2024 | $0.68 |
| Jun 25, 2024 | Jun 28, 2024 | $1.25 |
| Mar 25, 2024 | Mar 28, 2024 | $0.68 |
| Dec 26, 2023 | Dec 29, 2023 | $0.68 |
| Sep 27, 2023 | Sep 29, 2023 | $0.68 |
SURI Risk
- 30.0%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.44
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −47.7%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.14
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
SURI Cost
- The middle half of US Active Equity funds
- Median 0.70%
119 of the 124 US Active Equity funds charge less.